Kerr Jonathan R, Tyrrell David A J
Department of Microbiology, Royal Brompton Hospital, National Heart & Lung Institute, Imperial College London, UK.
Curr Pain Headache Rep. 2003 Oct;7(5):333-41. doi: 10.1007/s11916-003-0031-3.
Human parvovirus B19 infection has been associated with various clinical manifestations of a rheumatic nature such as arthritis, fatigue, and chronic fatigue syndrome (CFS), which can persist for years after the acute phase. The authors have demonstrated recently that acute B19 infection is accompanied by raised circulating levels of IL-1b, IL-6, TNF-a, and IFN-g and that raised circulating levels of TNF-a and IFN-g persist and are accompanied by MCP-1 in those patients who develop CFS. A resolution of clinical symptoms and cytokine dysregulation after intravenous immunoglobulin (IVIG) therapy, which is the only specific treatment for parvovirus B19 infection, also has been reported. Although CFS may be caused by various microbial and other triggers, that triggered by B19 virus is clinically indistinguishable from idiopathic CFS and exhibits similar cytokine abnormalities and may represent an accessible model for the study of CFS.
人细小病毒B19感染与多种风湿性临床表现有关,如关节炎、疲劳和慢性疲劳综合征(CFS),这些症状在急性期后可能持续数年。作者最近证明,急性B19感染伴随着循环中IL-1b、IL-6、TNF-α和IFN-γ水平的升高,并且在发展为CFS的患者中,TNF-α和IFN-γ的循环水平持续升高,并伴有MCP-1。静脉注射免疫球蛋白(IVIG)治疗是细小病毒B19感染的唯一特异性治疗方法,治疗后临床症状和细胞因子失调得到缓解的情况也有报道。虽然CFS可能由多种微生物和其他诱因引起,但由B19病毒引发的CFS在临床上与特发性CFS无法区分,且表现出相似的细胞因子异常,可能是研究CFS的一个可及模型。